Alzheimer's Disease Research

The GARNET Study

Click Here to participate


Research shows that mice exposed to flickering lights experience a reduction in brain plaques associated with Alzheimer’s disease. The GARNET Study is investigating whether similar effects are experienced by humans.

This research effort is led by our Translational Research team and focuses on optimizing our technology. This study is not intended to treat Alzheimer’s disease. Participation is compensated.

Our Design

The GARNET Study aims to inform the development of a therapy for Alzheimer’s disease.

Sensory Stimulation

Feasibility Testing

Placebo Controlled

In-Office Visits

One to Three Visits, Two to Three Hours Each Visit



This survey will determine your eligibility for participation in our study. If you qualify, our team will reach out to provide additional details and next steps.


Compensation is provided if you are enrolled in any of our study visits.

Participation in The GARNET Study does not give you preferential treatment for enrollment in our clinical trials. Participation will not necessarily prevent you from being considered for our clinical trials.

Eligibility Criteria

Men and women living in the Greater Boston area
55+ years old
Adults experiencing early symptoms of Alzheimer’s disease such as unclear thinking and memory loss

Study Visits 

If you take part in The GARNET Study, you can expect some of the following assessments. These assessments will vary across study arms and from visit to visit.

Daily + Weekly Surveys 
Vitals: Heart Rate, EEG 
Questionnaires + Cognitive Tests and Tasks 
Movement Tracking 

Our Approach

Alzheimer’s disease is characterized by the build-up of sticky plaques and tangles of specific proteins in the brain. These proteins are called beta-amyloid and tau. Researchers believe these proteins lead to the progression of Alzheimer’s disease.

Experts in Alzheimer’s disease theorize that reducing or preventing beta-amyloid deposits or tau tangles in the brain could help to slow or stop disease progression.

Recent research demonstrated that flickering lights reduced brain plaques and tau proteins associated with Alzheimer’s disease in mice. The GARNET Study is translating this research for human application in order to develop a possible therapy for Alzheimer’s disease.

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Consent to display content from Youtube
Consent to display content from Vimeo
Google Maps
Consent to display content from Google